ティナイ医師は、アナドル医療センターにて泌尿器科腫瘍の低侵襲手術を専門とし、高度な処置を精密に行います。
Ofer Merimsky医師は、Sourasky Medical Centerの軟部組織・骨腫瘍ユニットを率いており、高度な腫瘍治療を専門としています。
アンドレアス・セスターヘン教授は腫瘍の低侵襲治療を専門とし、小さな切開からロボット手術を行います。
アントニオ・アルカラス医師は、テノン・メディカル・センターにて、腹腔鏡下腎摘出術を含む500件以上の低侵襲泌尿器科手術を行ってきました。
ソラック医師はがん治療を専門としており、ハジェテペ大学がん研究所でのフェローシップ研修とMDアンダーソンがんセンターでの経験を有しています。
マルクス・ホイザー教授（医学博士）は、泌尿器腫瘍外科を専門とし、40以上の科学論文を執筆しています。
イリーナ・ステファンスキー博士は、テルアビブのイヒロフ医療センターの腫瘍入院部門のディレクターです。臨床腫瘍学と内科を専門としています。ステファンスキー博士は2000年からイスラエルで医師免許を保持しています。乳がん、胃がん、肝臓がんなどの悪性腫瘍を含むさまざまな癌を治療しています。
准教授のユスフ・アチクギョズ博士は、オハイオ州立大学での研究を含む、医療腫瘍学における広範なトレーニングを受けています。
ヒューズ・ヒョン医師は、ソラスキー医療センターにて低侵襲手術およびロボット手術を専門としており、精度と患者の回復に重点を置いています。
認定がんセンターの主任医師 – ヴィオラ・フォックス博士は、血液腫瘍疾患の高度な治療を専門としています。
准教授のタフシン・オザトリは、イスティニエ・リヴ大学病院で乳がん、肺がん、消化器がんを専門としています。
アレムダル医師は、トルコ有数の医療機関であるアクデニズ大学で広範なトレーニングを受けた腫瘍内科の専門医です。
アウアラ・ヒューバート医師は、36 年の腫瘍学の専門知識をハダサ医療センターにもたらし、腫瘍内科と放射線療法の両方を専門としています。
Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.
1980–1985: Completed doctoral studies at Nagasaki University, Japan
1968–present: Department of Radiology, Chinese PLA General Hospital
1988: Third Prize of the Military Science and Technology Progress Award
1989–present: Member of Radiological Society of North America(RSNA)
1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA
1991: Second Prize of the Military Science and Technology Progress Award
1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology
1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
1993: Granted the Lifetime Special Government Allowance of the State Council
1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology
1994: Third Prize of the Military Science and Technology Progress Award
1997: Second Prize of the Military Science and Technology Progress Award
1997–2009: Standing Member of Chinese Society of Radiology
1999: Third Prize of the Military Science and Technology Progress Award
1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology
2002: Second Prize of the Military Science and Technology Progress Award
2005: Third Prize of the Military Science and Technology Progress Award
Member of Radiological Society of North America(RSNA)
Standing Member of Chinese Society of Radiology
Group Leader of the Group of Intervention of Chinese Journal of Radiology
Deputy Director Member of Chinese Society of Interventional Oncology
Director Member of Beijing Medical Association Society of Interventional Radiology
Deputy Chief Editor of Chinese Journal of Medical Image Technology
Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army
Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
Awarded the Special Government Allowance of the State Council
Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.
Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”
Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.
In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.
Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.
In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.
Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.
From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.
Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.
1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.
Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.
2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.
Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.
3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.
Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.
4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.
Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.
5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.
Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.
6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.
Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.
7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.
Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.
8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.
Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.
1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.
2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.
3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.
1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.
2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.
3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.
4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.
ニール・クラインマン医師は、シェバ医療センターの結石・内視鏡泌尿器科ユニットを統括しています。複雑な腫瘍に対する腎温存レーザー手術のパイオニアです。フォーブス誌とResultMedにより、2025年および2026年のイスラエルのベストドクターに選出されました。クラインマン医師は、がん治療中に臓器機能を維持するための独自のデュアルレーザーシステムを使用しています。
イ・スンウン教授は小児外科および消化器外科を専門とし、複雑な症例において豊富な経験を有しています。
ガレニア病院にて腹腔鏡下腎摘除術の専門知識を持つ認定外科腫瘍医。
Gul Alco教授は放射線腫瘍学を専門とし、イスタンブールのトップ機関で豊富な学術的および臨床的経験を有しています。
| 順位 | 医師 | 経験 | 適合する方 | 特色 | クリニックと所在地 | 診察 |
|---|---|---|---|---|---|---|
| #1 | 23年の経験 | 泌尿器がんの低侵襲手術 | 泌尿器がんに対する高度な低侵襲技術を専門としています。泌尿器腫瘍学会の理事を務めており、最先端の医療実践を保証しています。 | トルコ | から $215 | |
| #2 | 41年の経験 | 軟部組織・骨腫瘍学 | ギュスターヴ・ルシー研究所での高度な研修を受けた軟部組織・骨肉腫の専門家。ESMO肉腫ファカルティおよびASCOのメンバーであり、研究への貢献も多大です。 | イスラエル | から $950 | |
| #3 | 26年の経験 | 腫瘍の低侵襲治療 | 最小限の切開によるロボット手術を専門とする。ゾーリンゲン・クリニックの主任医師であり、78本の科学論文の著者。 | ドイツ | お問い合わせください | |
| #4 | 38年の経験 | 低侵襲腎摘出術 | ロボット支援による腹腔鏡下腎摘出術を実施。スペイン有数の泌尿器科部門を率いる。主要な国際泌尿器科学会の会員。 | スペイン | お問い合わせください | |
| #5 | 20年の経験 | がん関連の腎摘出術症例 | ハジェテペ大学がん研究所で腫瘍学のフェローシップ研修を修了しており、複雑ながん症例の経験が豊富。MDアンダーソンがんセンターでの勤務経験あり。 | トルコ | から $100 | |
| #6 | 31年の経験 | 腹腔鏡下腎摘出術 | 泌尿器腫瘍外科および腹腔鏡下腎摘出術を専門とする。研究と教育における卓越した功績により受賞歴あり。 | ドイツ | お問い合わせください | |
| #7 | 10年の経験 | 臨床試験への参加 | 最先端の第III相腫瘍学試験に積極的に取り組んでいる。ASCO会員であり、オハイオ州立大学での研究経験を持つ。臨床研究のための複数のCITI認定を保持。 | トルコ | お問い合わせください | |
| #8 | 43年の経験 | 低侵襲腎摘出術 | 腹腔鏡およびロボット手術を専門とし、精度と迅速な回復を提供します。ソラスキー医療センターの認定外科医。 | イスラエル | お問い合わせください | |
| #9 | 14年の経験 | 血液腫瘍疾患 | 免疫療法や分子診断を含む高度な治療を行う認定がんセンターを率いています。がん治療の画期的な研究に積極的に取り組んでいます。 | ドイツ | お問い合わせください | |
| #10 | 2016年の経験 | 乳がん、肺がん、消化器がん | 准教授としての学術的評価を受け、複数の癌種を専門としています。トルコの様々な腫瘍科での経験が豊富です。 | トルコ | お問い合わせください |